このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Mach7 Technologies 配当金

配当金基準チェック /06

Mach7 Technologies配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	1.0%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-AU$0.023
3年後の配当利回り予想	0%

最近の配当金アップデート

更新なし

Recent updates

Mach7 Technologies Limited (ASX:M7T) Analysts Are More Bearish Than They Used To Be

Jan 29

We're Interested To See How Mach7 Technologies (ASX:M7T) Uses Its Cash Hoard To Grow

Apr 28

An Intrinsic Calculation For Mach7 Technologies Limited (ASX:M7T) Suggests It's 47% Undervalued

Oct 24

Are Investors Undervaluing Mach7 Technologies Limited (ASX:M7T) By 37%?

Jun 23

Is Mach7 Technologies Limited (ASX:M7T) Potentially Undervalued?

May 19

Is There An Opportunity With Mach7 Technologies Limited's (ASX:M7T) 47% Undervaluation?

Nov 10

Mach7 Technologies Limited's (ASX:M7T) Analyst Just Slashed This Year's Estimates

Jul 27

Upgrade: The Latest Revenue Forecasts For Mach7 Technologies Limited (ASX:M7T)

Feb 19

The Mach7 Technologies (ASX:M7T) Share Price Is Up 303% And Shareholders Are Delighted

Jan 27

Is There An Opportunity With Mach7 Technologies Limited's (ASX:M7T) 46% Undervaluation?

Dec 06

決済の安定と成長

配当データの取得

安定した配当: M7Tの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: M7Tの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Mach7 Technologies 配当利回り対市場

M7T 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (M7T)	n/a
市場下位25% (AU)	2.7%
市場トップ25% (AU)	6.6%
業界平均 (Healthcare Services)	1.0%
3年後のアナリスト予想 (M7T)	0%

注目すべき配当: M7Tは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: M7Tは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: M7Tの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: M7Tが配当金を報告していないため、配当金の持続可能性を計算できません。

Mach7 Technologies 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Mach7 Technologies Limited to Report Q3, 2024 Results on Apr 24, 2024

Mach7 Technologies Limited to Report First Half, 2024 Results on Feb 29, 2024

Mach7 Technologies Limited (ASX:M7T) Analysts Are More Bearish Than They Used To Be

Consensus EPS estimates fall by 120%

Forecast breakeven date pushed back to 2026

Mach7 Technologies Limited to Report Q2, 2024 Results on Jan 31, 2024

Price target decreased by 7.6% to AU$1.23

Mach7 Technologies (ASX:M7T) Is In A Strong Position To Grow Its Business

Insufficient new directors

Mach7 Technologies Limited Appoints Rebecca Thompson as Director

Independent Non-Executive Director exercised options to buy AU$158k worth of stock.

Consensus EPS estimates upgraded to AU$0.0045 loss, revenue downgraded

Mach7 Technologies Limited to Report Q1, 2024 Results on Oct 31, 2023

New minor risk - Market cap size

Price target decreased by 9.7% to AU$1.33

Is Now The Time To Look At Buying Mach7 Technologies Limited (ASX:M7T)?

CEO, MD & Director exercised options and sold AU$65k worth of stock

Mach7 Technologies Limited Announces Board Changes, Effective 16 November 2023

Estimating The Fair Value Of Mach7 Technologies Limited (ASX:M7T)

Forecast breakeven date pushed back to 2025

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mach7 Technologies Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mach7 Technologies Limited, Annual General Meeting, Nov 16, 2023

Mach7 Technologies Limited to Report Q4, 2023 Results on Jul 31, 2023

Price target increased by 13% to AU$1.49

Independent Non-Executive Chairman exercised options to buy AU$140k worth of stock.

Why Mach7 Technologies Limited (ASX:M7T) Could Be Worth Watching

Now 21% undervalued after recent price drop

We're Interested To See How Mach7 Technologies (ASX:M7T) Uses Its Cash Hoard To Grow

Now 20% undervalued after recent price drop

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in 1H 2022)

Consensus EPS estimates upgraded to AU$0.009 loss, revenue downgraded

Mach7 Technologies Limited Announces Change of Company Secretary

Mach7 Technologies Limited Provides Revenue Guidance for the Year 2023

Mach7 Technologies Limited Announces Executive Changes, Effective January 1, 2023

Consensus forecasts updated

An Intrinsic Calculation For Mach7 Technologies Limited (ASX:M7T) Suggests It's 47% Undervalued

Mach7 Technologies Limited, Annual General Meeting, Nov 17, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$1.27

Mach7 Technologies Limited to Report Q4, 2022 Results on Aug 29, 2022

Mach7 Technologies Limited to Report Q4, 2022 Results on Jul 21, 2022

Are Investors Undervaluing Mach7 Technologies Limited (ASX:M7T) By 37%?

Is Mach7 Technologies Limited (ASX:M7T) Potentially Undervalued?

Price target decreased to AU$1.38

Price target decreased to AU$1.38

Consensus forecasts updated

Consensus forecasts updated

First half 2022 earnings: EPS and revenues miss analyst expectations

Mach7 Technologies Limited to Report First Half, 2022 Results on Feb 28, 2022

Mach7 Technologies Limited to Report Q2, 2022 Results on Jan 31, 2022

Is There An Opportunity With Mach7 Technologies Limited's (ASX:M7T) 47% Undervaluation?

Company Secretary Jennifer Pilcher has left the company

Mach7 Technologies Limited Provides Earning Guidance for the Calendar Year 2021

Mach7 Technologies Limited's (ASX:M7T) Analyst Just Slashed This Year's Estimates

Price target decreased to AU$1.56

First half 2021 earnings released: AU$0.031 loss per share (vs AU$0.004 profit in 1H 2020)

Upgrade: The Latest Revenue Forecasts For Mach7 Technologies Limited (ASX:M7T)

Price target raised to AU$1.68

Analysts update estimates

Mach7 Technologies Limited to Report First Half, 2021 Results on Feb 18, 2021

New 90-day high: AU$1.57

Mach7 Technologies Limited Provides Update on Its Project with the Hospital Authority of Hong Kong

The Mach7 Technologies (ASX:M7T) Share Price Is Up 303% And Shareholders Are Delighted

Mach7 Technologies Limited Wholly-Owned Subsidiary Signs a Contract Amendment with Adventist Health System

New 90-day high: AU$1.34

Mach7 Technologies Limited Appoints Philippe Houssiau as Non-Executive Director, Effective 1 January 2021

Is There An Opportunity With Mach7 Technologies Limited's (ASX:M7T) 46% Undervaluation?

Mach7 Technologies Announces the Next Phase in Empowering AI Within Radiology Reading Workflow to Drive Better Clinical Outcomes

New 90-day high: AU$1.18

配当金基準チェック /06